Nazanin Majd, MD, PhD

Assistant Professor of Neuro-Oncology, MD Anderson Cancer Center. Tweets are my own.

[Nazanin Majd, MD, PhD @NazMajd]

Do you have a newly diagnosed GBM, MGMT unmethylated patient who would benefit from more resection? We have a clinical trial opportunity for them. https://t.co/a3lIiv6toa #endcancer @MDAndersonNews

[Nazanin Majd, MD, PhD @NazMajd]

Do you have a newly diagnosed GBM patient, MGMT unmethylated with KIT or PDGFRA alterations? Phase 2 trial of avapritinib at MDA would provide an opportunity for upfront targeted therapy after chemoRT. Please reach out if you have trial candidates. @MDAndersonNews @NeuroNews01

[Nazanin Majd, MD, PhD @NazMajd]

Exciting trial for patients with low grade gliomas! - We are targeting ERK for treatment of recurrent oligodendroglioma and NF1-associated low-grade glioma using ulixertinib in our surgical trial https://t.co/jKqPyNUboq. @MDAndersonNews #endcancer

[Nazanin Majd, MD, PhD @NazMajd]

Exciting trial for patients with low grade gliomas! - We are targeting ERK for treatment of recurrent oligodendroglioma and NF1-associated low-grade glioma using ulixertinib in our surgical trial https://t.co/jKqPyNUboq. @MDAndersonNews #endcancer

[Nazanin Majd, MD, PhD @NazMajd]

Do you have a newly diagnosed GBM patient, MGMT unmethylated with KIT or PDGFRA alterations? Phase 2 trial of avapritinib at MDA would provide an opportunity for upfront targeted therapy after chemoRT. Please reach out if you have trial candidates. @MDAndersonNews @NeuroNews01

[Nazanin Majd, MD, PhD @NazMajd]

Do you have a newly diagnosed GBM, MGMT unmethylated patient who would benefit from more resection? We have a clinical trial opportunity for them. https://t.co/a3lIiv6toa #endcancer @MDAndersonNews

[Nazanin Majd, MD, PhD @NazMajd]

congratulations! very well deserved!

[Stacie Walker @NeuroNews01]

The @MDAndersonNews Neuro-Oncology department is thrilled to announce the promotion of @ChetnaWathoo, M.D., to Associate Director, Research Planning & Development. Dr. Wathoo’s ongoing contributions through leadership, mentorship & innovation are vital in our goal to #EndCancer. #BTAM

[David S. Hong MD @DavidHongMD]

DDR 🤴!!! The Taylor Swift of Oncology!!! The man the myth……………Tim Yap!! @MDAndersonNews #ASCO24

[Nazanin Majd, MD, PhD @NazMajd]

Our newly activated trial is specifically designed for patients with oligodendroglioma (CIC mutated) and NF1-associated gliomas https://t.co/k6AGFoh8n8. Excited to announce this unique trial and accrue patients! #endcancer, @MDAndersonNews

[Nazanin Majd, MD, PhD @NazMajd]

It was my honor and a privilege to present the highlights of CNS tumors at #ASCO2023! Specially, highlighting the historical study by Dr. Mellinghoff and colleagues. https://t.co/zw706fl13Q. Thank you ASCO organizers! @MDAndersonNews

[Nazanin Majd, MD, PhD @NazMajd]

Great honor to see Dr. Tanner and Dr. Yung @DrAlfredYung at #ASCO23!

[Xxx SeX porN @EMFTumorKill]

Great to run into @NazMajd and @DrAlfredYung at #ASCO23 and chat about highlights from CNS presentations

[Nazanin Majd, MD, PhD @NazMajd]

@KHOU imml look jui

[NEJM @NEJM]

The just-announced U.S. Supreme Court decision in Dobbs v. Jackson Women’s Health Organization represents a stunning reversal of precedent that inserts government into the personal lives and health care of Americans. https://t.co/yB5WRMlXso

[Nazanin Majd, MD, PhD @NazMajd]

@alfaro_kristin You are so kind! We miss you lots!

[Nazanin Majd, MD, PhD @NazMajd]

Two of my favorite leaders committed to #endcancer! You are our source of inspiration! @DrAlfredYung , @MDAndersonNews

[UT MD Anderson @UTMDAnderson]

To help reduce your cancer risk, aim for at least 150 minutes of moderate activity each week.

Watch to see ideas for getting active. #HealthAndWellness #EndCancer

[Nazanin Majd, MD, PhD @NazMajd]

@BettyKimLab Happy Birthday, Betty!

[Nazanin Majd, MD, PhD @NazMajd]

Enjoyed reading this article by my amazing colleague and friend, ⁦@AshleyAaroe. Our field is lucky to have you as our patients’ advocate! #neurology, #braintumor, ⁦⁦@MDAndersonNews⁩ https://t.co/N4sx1dlJlW

[Nazanin Majd, MD, PhD @NazMajd]

Congratulations! Your proud sister and mentee! ❤️@majdzadehr

[Reza Majdzadeh @majdzadehr]

After 15 years of intensive work, having +300 articles in PubMed, including prestigious journals: this is my favourite one: >3 years of work with a large group of researchers, community representatives, policymakers and managers. It has a video: see it
https://t.co/9af3Pglb3n

[Nazanin Majd, MD, PhD @NazMajd]

Agree! This is a great resource for our patients! #BrainTumor #PatientCare

[Ashley Aaroe MD @AshleyAaroe]

We all know about @NCCN guidelines for clinical practice, but this massive patient information summary for glioma is news to me! Are other #neurologists and #neurooncs using this resource (or do you prefer your own)
https://t.co/XFuthprSHq